Litcius/Paper detail

Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview

Claire Amaris Hobson, Gautier Pierrat, Olivier Tenaillon, Stéphane Bonacorsi, Béatrice Berçot, Ella Jaouen, Hervé Jacquier, André Birgy

2022Antimicrobial Agents and Chemotherapy208 citationsDOIOpen Access PDF

Abstract

First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates. These beta-lactamases conferred resistance to most beta-lactams including carbapenems but remained susceptible to new beta-lactam/beta-lactamase inhibitors, such as ceftazidime-avibactam.

Topics & Concepts

Ceftazidime/avibactamAvibactamKlebsiella pneumoniaeCeftazidimeBeta-Lactamase InhibitorsMicrobiologyBiologyDrug resistanceAntibioticsGeneticsEscherichia coliBacteriaGenePseudomonas aeruginosaAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyVibrio bacteria research studies
Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview | Litcius